Improving risk equalization for individuals with persistently high costs: Experiences from the Netherlands

Although this study provides useful insights in the possibilities for improving RE-models for persistently high-cost individuals, improving compensation remains challenging and dependent on the ongoing debate regarding coverage and reimbursement of expensive drugs.